Zach Hartman
Seeking Alpha
Atlanta, GA, United States
Contact Zach
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Zach:
3 Things In Biotech, May 28: Making Deals In The Asian Market
Karyopharm strikes a deal that can help them in Asia. BioMarin scores its approval in phenylketonuria. AcelRx breathes a short sigh of relief. → Read More
Mining ASCO 2018's Gold, Part 5: There's A Lot To Look Forward To
Today's edition focuses on some potentially important developments in targeted therapy for various tumor types. Daiichi Sankyo gets particular focus in this one → Read More
3 Things In Biotech, May 26: Immunotherapy Strikes Lung Cancer Yet Again
AstraZeneca marks a new historic achievement in competitive lung cancer space. bluebird bio lands a breakthrough in another rare genetic disorder. Genmab's CD20 → Read More
Mining ASCO 2018's Gold, Part 4: Radiation Glows In Breast And Brain
Today's mining focuses in part on the emerging combinations of radiation and immunotherapy. In particular, breast and brain cancer are the focus here. Several o → Read More
3 Things In Biotech, May 25: A CLL Game Changer
AbbVie is about to change the CLL game again? Little Krystal Biotech looks to attack epidermolysis bullosa. CytomX allowed to unleash its probody drug conjugate → Read More
Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain
Bridging from breast cancer into brain cancer, there are some highly enticing footholds in this year's data. Watch out for Bayer in the brain! ASCO continues to → Read More
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
Merck immunotherapy makes major progress in a tough lung cancer space. Cosmo Pharmaceuticals shares some bad news from the FDA. Pfizer scores a breakthrough for → Read More
Mining For ASCO 2018's Gold, Part 2: Some Studies Trend Toward Negative
ASCO is filled to the brim with studies that will not likely show up on your radar. Read here to get caught up! Immutep shows off interesting LAG-3 immunotherap → Read More
3 Things In Biotech, May 23: Gene Therapy Continues To Promise
Astellas partner gets on with a non-injected wet AMD drug. Aileron rolls into lymphoma. Spark springs out its gene therapy. → Read More
Mining For ASCO 2018's Gold, Part 1: Early Breast Cancer Has Some Sheen
Read up on upcoming potentially actionable events for the mid- to long-term coming out of 2018's biggest cancer meeting. Puma's drug seems to work a lot better → Read More
3 Things In Biotech, May 22: Breast Cancer Disruption!
Immunomedics eyes the finish for their ADC in breast cancer. Foundation Medicine lays the groundwork for major testing landscape. Abeona updated on Sanfilippo B → Read More
3 Things In Biotech, May 21: A Powerful New Immunotherapy?
Novartis publishes favorable data for Ilaris in fever syndromes. Inovio to present updated data in prostate cancer immunotherapy. Cosmo Pharmaceuticals looks to → Read More
3 Things In Biotech, May 20: You Want Some Good News?
BeiGene launches a me too PARP inhibitor study in China. Abeona Therapeutics shows off more promising data in wound healing. BioLine shows off a winner in AML a → Read More
3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara's Immunotherapy Data
Bristol-Myers looking to checkmate adjuvant melanoma. Oncolytics is about to strike for pancreatic cancer. Atara to show off immunotherapy data at EHA. → Read More
3 Things In Biotech, May 18: Exelixis Digs Europe, GT Bio Wants A Shot, Agios Bags Another
Exelixis extends its first-line reach to Europe. GT Biopharma seeks to advance a new platform into AML treatment. Agios will show off its next big AML drug at t → Read More
3 Things In Biotech, May 17: Insmed's Approval Chance, Pfizer Finally Proves Similar, Eagle Ascends
The FDA gives Insmed their day in the chair. Pfizer's biosimilar epoetin finally makes its way to the market. Eagle Pharma extends its key asset's approval. → Read More
3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer
Lilly shows late mixed data for migraine treatment. Aerie Pharmaceuticals eyes the finish line for glaucoma. Rexahn inches along in early-stage pancreatic cance → Read More
The Ongoing Loxo Thesis, Part 2: The Journey Doesn't End With Larotrectinib
Larotrectinib is Loxo Oncology's golden goose, but it won't rest on this drug alone. In this article, I consider the impact of the company's other Trk inhibitor → Read More
3 Things In Biotech, May 10: AstraZeneca Expands, Roche Digs In, OncoSec Gets A Collab
AstraZeneca expands the PARP program in Europe. Roche digs its heels into CLL just a bit more. OncoSec hooks up with Merck to start a new trial. → Read More
3 Things In Biotech, May 9: New AML Therapy Imminent? AVEO Hedges, Rockwell Boosts Iron
Daiichi Sankyo gets an in with an AML subgroup. AVEO delays a critical stage of a critical trial. Rockwell Medical shows early signs of rocking in anemia. → Read More